Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4545
- Book/Share 8.5908
- PB 5.5666
- Debt/Equity 2.9466
- CurrentRatio 1.2789
- ROIC 0.1085
- MktCap 96991912800.0
- FreeCF/Share 6.4431
- PFCF 7.4119
- PE 17.8626
- Debt/Assets 0.5544
- DivYield 0.0642
- ROE 0.3193
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
2 Wonderful Dividends At Bargain Basement Prices
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
Read More
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
Read More
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
Published: June 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
Read More
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Read More
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
Published: June 24, 2025 by: Reuters
Sentiment: Negative
Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
Read More
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.
Read More
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Read More
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
Read More
BMY Reports Positive Data on Sotyktu From Arthritis Study
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Read More
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider All right.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.
Read More
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating pick versus higher-risk, growth-oriented BioNTech.
Read More
Bristol Myers Collaborates With BNTX for Oncology Candidate
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Read More
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The companies will work on transforming outcomes for patients with difficult-to-treat solid tumors, Boerner said.
Read More
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Read More
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Published: June 02, 2025 by: Market Watch
Sentiment: Positive
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
Read More
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.
Read More
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
Read More
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Read More
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears safe as well, as observed in the management's recent payout hike and the still rich cash flows despite the ongoing patent cliff impact. This is on top of the raised FY2025 guidance, given the accelerating Growth Portfolio revenue profile compared to a year ago, thanks to the M&A activities and intensified R&D efforts.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100